Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single-Blind, Randomized, Placebo-Controlled Study of Capravirine (AG1549) in Combination With Viracept and Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Subjects Who Failed an Initial Nonnucleoside Reverse Transcriptase Inhibitor Containing Regimen

NCT00004985 is registered in ClinicalTrials.gov with Agouron Pharmaceuticals as lead sponsor.

NCT NCT00004985
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00004985 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single-Blind, Randomized, Placebo-Controlled Study of Capravirine (AG1549) in Combination With Viracept and Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Subjects Who Failed an Initial Nonnucleoside Reverse Transcriptase Inhibitor Containing Regimen
Lead sponsor
Agouron Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2000
Completion date
Not reported
Enrollment
75
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections